1160182-44-4

Basic information

• Product Name: 4-bromo-3-(1,3-dioxolan-2-yl)phenol
• Synonyms: 4-bromo-3-(1,3-dioxolan-2-yl)phenol
• CAS NO: 1160182-44-4
• Molecular Weight: 245.073
• Mol File: 1160182-44-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-bromo-3-(1,3-dioxolan-2-yl)phenol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-3-(1,3-dioxolan-2-yl)phenol(1160182-44-4)
• EPA Substance Registry System: 4-bromo-3-(1,3-dioxolan-2-yl)phenol(1160182-44-4)

Safety Data

• Hazardous Substances Data: 1160182-44-4(Hazardous Substances Data)

Usage

General Description

4-bromo-3-(1,3-dioxolan-2-yl)phenol is a chemical compound consisting of a bromine atom and a phenol group attached to a 3-(1,3-dioxolan-2-yl) substituent. It is commonly used as a building block in organic synthesis and pharmaceutical research. 4-bromo-3-(1,3-dioxolan-2-yl)phenol has potential applications in the development of pharmaceutical drugs, agrochemicals, and other industrial products. Its molecular structure and properties make it useful for the creation of other organic compounds as well. It is important to handle this chemical with caution and follow safety protocols due to its potential hazardous and toxic nature.

Upstream product

• 2973-80-0 2-bromo-5-hydroxybenzaldehyde 
• 107-21-1 ethylene glycol 

Downstream Products

• 1217366-74-9 4-[4-bromo-3-(1,3-dioxolan-2-yl)phenoxy]benzonitrile 
• 1217366-73-8 C₁₆H₁₂BrNO₃ 
• 1187189-91-8 C₁₉H₂₂BrNO₅S 
• 1187189-87-2 C₂₀H₂₃BrN₂O₅S 
• 1106867-72-4 (4-ethoxy-2-formylphenyl) boronic acid 
• 1160182-48-8 C₁₇H₁₈BrNO₄S 

Relevant articles and documents

Design, Synthesis, and Characterization of Ogerin-Based Positive Allosteric Modulators for G Protein-Coupled Receptor 68 (GPR68)

G protein-coupled receptor 68 (GPR68) is an understudied orphan G protein-coupled receptor (GPCR). It is expressed most abundantly in the brain, potentially playing important roles in learning and memory. Pharmacological studies with GPR68 have been hinde

Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis

A series of phenoxy benzoxaboroles were synthesized and screened for their inhibitory activity against PDE4 and cytokine release. 5-(4-Cyanophenoxy)-2,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2728) showed potent activity both in vitro and in vivo. This compound is now in clinical development for the topical treatment of psoriasis and being pursued for the topical treatment of atopic dermatitis.